Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
May 21, 2021
- Give AstraZeneca Shots to People Who Want, Regardless of Priority Order: Lawmakers
May 21, 2021
- Japan Govt Eyes Expedited Approval Process to Push Homegrown Vaccines
May 20, 2021
- LDP Panels Submit Proposal to PM for Commercialization of Japan-Made Vaccines
May 19, 2021
- LDP Study Group’s Draft Proposal Urges Price Maintenance for Patented Drugs
May 19, 2021
- Pharma to Govt: Maintain Prices of Patented Drugs, It’s the Global Standard
May 18, 2021
- MHLW Proposes Lifting Domestic Ban on Cannabis-Derived Drugs, Seeking “Ingredient-Based” Regulation
May 18, 2021
- Japan’s 1st Sakigake-Designated Oncolytic Virus Up for Advisory Panel Review on May 24
May 18, 2021
- AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
- Japan, Pfizer Agree on 50 Million Extra Vaccine Doses by Sept-End
May 17, 2021
- Eisai’s EZH2 Inhibitor Up for PAFSC Review on May 28
May 17, 2021
- Daiichi Sankyo CEO Urges Rethink of Vaccine Approval System
May 17, 2021
- LDP Project Team Urges Overhaul of Unpredictable Pricing System: Proposal
May 14, 2021
- LDP Panels Call for Emergency Approval Process, Eyes Japan Made Vaccines
May 14, 2021
- No Serious Safety Concerns Detected for Comirnaty: MHLW Safety Panels
May 14, 2021
- 1st Oral SMA Med Risdiplam Up for PAFSC Review on May 26
May 14, 2021
- Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
May 13, 2021
- Chuikyo OKs Re-Pricing for Tecentriq, Vyndaqel; 3 I/O Peers Challenge Cuts in Vain
May 13, 2021
- Operating Profit Rate for Cost-Based Method Updated to 15.5%: Chuikyo
May 13, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…